Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma

Arthritis and Rheumatism

Volumn 63, Issue 5, 2011, Pages 1405-1415

  Castelino, Flavia V ^a   Seiders, Jon ^b   Bain, Gretchen ^b   Brooks, Sarah F ^a   King, Christopher D ^b   Swaney, James S ^b   Lorrain, Daniel S ^b   Chun, Jerold ^c   Luster, Andrew D ^a   Tager, Andrew M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Amira Pharmaceuticals   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AM 095; BLEOMYCIN; COLLAGEN; DERMATOLOGICAL AGENT; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 1; LYSOPHOSPHATIDIC ACID RECEPTOR 2; PHOSPHATE BUFFERED SALINE; SMAD2 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; FEMALE; GENE DELETION; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SCLERODERMA; SKIN FIBROSIS; SKINFOLD THICKNESS;

ANIMALS; BLEOMYCIN; DISEASE MODELS, ANIMAL; FIBROSIS; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; RECEPTORS, LYSOPHOSPHATIDIC ACID; SCLERODERMA, SYSTEMIC; SKIN;

EID: 79955559412     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30262     Document Type: Article

References (43)

1. Abraham DJ, Varga J,. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005; 26: 587-95. (Pubitemid 41726446)
2. Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, et al. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 2010; 50: 157-86.
3. 1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008; 14: 45-54.
4. q. Am J Pathol 2009; 174: 1264-79.
5. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, et al. A mechanism for regulating pulmonary inflammation and fibrosis: the integrin αvβ6 binds and activates latent TGF β1. Cell 1999; 96: 319-28. (Pubitemid 29077586)
6. Tokumura A, Carbone LD, Yoshioka Y, Morishige J, Kikuchi M, Postlethwaite A, et al. Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis. Int J Med Sci 2009; 6: 168-76.
7. Mazereeuw-Hautier J, Gres S, Fanguin M, Cariven C, Fauvel J, Perret B, et al. Production of lysophosphatidic acid in blister fluid: involvement of a lysophospholipase D activity. J Invest Dermatol 2005; 125: 421-7.
8. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, et al. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999; 112: 456-62. (Pubitemid 29171935)
9. Wu M, Varga J,. In perspective: murine models of scleroderma. Curr Rheumatol Rep 2008; 10: 173-82.
10. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 2003; 100: 12319-24. (Pubitemid 37271558)
11. Takagawa S, Lakos G, Mori Y, Yamamoto T, Nishioka K, Varga J,. Sustained activation of fibroblast transforming growth factor-β/Smad signaling in a murine model of scleroderma. J Invest Dermatol 2003; 121: 41-50. (Pubitemid 36900453)
12. Mori Y, Hinchcliff M, Wu M, Warner-Blankenship M, Lyons KM, Varga J,. Connective tissue growth factor/CCN2-null mouse embryonic fibroblasts retain intact transforming growth factor-β responsiveness. Exp Cell Res 2008; 314: 1094-104.
13. A1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci U S A 2000; 97: 13384-9.
14. 2. Mol Cell Biol 2002; 22: 6921-9.
15. Tager AM, Kradin RL, LaCamera P, Bercury SD, Campanella GS, Leary CP, et al. Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10. Am J Respir Cell Mol Biol 2004; 31: 395-404. (Pubitemid 39330949)
16. Desmouliere A, Chaponnier C, Gabbiani G,. Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 2005; 13: 7-12. (Pubitemid 40250424)
17. Abraham DJ, Eckes B, Rajkumar V, Krieg T,. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep 2007; 9: 136-43. (Pubitemid 46932720)
18. Hinz B,. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol 2007; 127: 526-37.
19. Werner S, Grose R,. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003; 83: 835-70. (Pubitemid 36828927)
20. Massague J, Seoane J, Wotton D,. Smad transcription factors. Genes Dev 2005; 19: 2783-810. (Pubitemid 41739965)
21. Demoyer JS, Skalak TC, Durieux ME,. Lysophosphatidic acid enhances healing of acute cutaneous wounds in the mouse. Wound Repair Regen 2000; 8: 530-7. (Pubitemid 32141457)
22. Balazs L, Okolicany J, Ferrebee M, Tolley B, Tigyi G,. Topical application of the phospholipid growth factor lysophosphatidic acid promotes wound healing in vivo. Am J Physiol Regul Integr Comp Physiol 2001; 280: R466-72.
23. Abraham D, Distler O,. How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther 2007; 9 Suppl 2: S2.
24. Sappino AP, Masouye I, Saurat JH, Gabbiani G,. Smooth muscle differentiation in scleroderma fibroblastic cells. Am J Pathol 1990; 137: 585-91. (Pubitemid 20280988)
25. Kissin EY, Merkel PA, Lafyatis R,. Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum 2006; 54: 3655-60. (Pubitemid 44737178)
26. Kundra V, Anand-Apte B, Feig LA, Zetter BR,. The chemotactic response to PDGF-BB: evidence of a role for Ras. J Cell Biol 1995; 130: 725-31.
27. Pietruck F, Busch S, Virchow S, Brockmeyer N, Siffert W,. Signalling properties of lysophosphatidic acid in primary human skin fibroblasts: role of pertussis toxin-sensitive GTP-binding proteins. Naunyn Schmiedebergs Arch Pharmacol 1997; 355: 1-7. (Pubitemid 27008445)
28. Cerutis DR, Dreyer A, Cordini F, McVaney TP, Mattson JS, Parrish LC, et al. Lysophosphatidic acid modulates the regenerative responses of human gingival fibroblasts and enhances the actions of platelet-derived growth factor. J Periodontol 2004; 75: 297-305. (Pubitemid 38372273)
29. Tangkijvanich P, Melton AC, Chitapanarux T, Han J, Yee HF,. Platelet-derived growth factor-BB and lysophosphatidic acid distinctly regulate hepatic myofibroblast migration through focal adhesion kinase. Exp Cell Res 2002; 281: 140-7. (Pubitemid 35373790)
30. i-protein-mediated activation of mitogen-activated protein kinase. Biochem J 2000; 352 Pt 1: 135-43.
31. Song J, Clair T, Noh JH, Eun JW, Ryu SY, Lee SN, et al. Autotaxin (lysoPLD/NPP2) protects fibroblasts from apoptosis through its enzymatic product, lysophosphatidic acid, utilizing albumin-bound substrate. Biochem Biophys Res Commun 2005; 337: 967-75. (Pubitemid 41447007)
32. Sonnylal S, Denton CP, Zheng B, Keene DR, He R, Adams HP, et al. Postnatal induction of transforming growth factor β signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum 2007; 56: 334-44. (Pubitemid 46106207)
33. Lakos G, Takagawa S, Chen SJ, Ferreira AM, Han G, Masuda K, et al. Targeted disruption of TGF-β/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 2004; 165: 203-17. (Pubitemid 38821828)
34. Gardner H, Shearstone JR, Bandaru R, Crowell T, Lynes M, Trojanowska M, et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006; 54: 1961-73. (Pubitemid 43877946)
35. Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 2008; 3: e2696.
36. Munger JS, Harpel JG, Gleizes PE, Mazzieri R, Nunes I, Rifkin DB,. Latent transforming growth factor-β: structural features and mechanisms of activation. Kidney Int 1997; 51: 1376-82. (Pubitemid 27239886)
37. Annes JP, Munger JS, Rifkin DB,. Making sense of latent TGFβ activation. J Cell Sci 2003; 116: 217-24. (Pubitemid 36163863)
38. Piazza GA, Ritter JL, Baracka CA,. Lysophosphatidic acid induction of transforming growth factors α and β: modulation of proliferation and differentiation in cultured human keratinocytes and mouse skin. Exp Cell Res 1995; 216: 51-64.
39. Ihn H, Yamane K, Kubo M, Tamaki K,. Blockade of endogenous transforming growth factor β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor β receptors. Arthritis Rheum 2001; 44: 474-80.
40. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K,. Increased expression levels of integrin αvβ5 on scleroderma fibroblasts. Am J Pathol 2004; 164: 1275-92. (Pubitemid 38387794)
41. 3 contributes to the establishment of autocrine TGF-β signaling in scleroderma fibroblasts. J Immunol 2005; 175: 7708-18. (Pubitemid 41713471)
42. 1 receptor activation promotes renal interstitial fibrosis. J Am Soc Nephrol 2007; 18: 3110-8. (Pubitemid 350223970)
43. Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Tomiya T, et al. Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity. Life Sci 2007; 81: 1009-15. (Pubitemid 47386006)